ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ and Miroslav PENKA. The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms. In vivo. Athens: International Institute of Anticancer Research, 2021, vol. 35, No 6, p. 3345-3353. ISSN 0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12632.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms
Authors ASWAD, Mohamed Hussam (760 Syrian Arab Republic, guarantor, belonging to the institution), Jarmila KISSOVÁ (203 Czech Republic, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Lucie ŘÍHOVÁ (203 Czech Republic, belonging to the institution) and Miroslav PENKA (203 Czech Republic, belonging to the institution).
Edition In vivo, Athens, International Institute of Anticancer Research, 2021, 0258-851X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher Greece
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.406
RIV identification code RIV/00216224:14110/21:00122607
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.21873/invivo.12632
UT WoS 000711693300017
Keywords in English Myeloproliferative neoplasm; microparticle; procoagulant activity; thrombosis; anagrelide; hydroxyurea
Tags 14110212, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 13/12/2021 13:12.
Abstract
Background/Aim: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). Patients and Methods: In a cohort of 206 patients with MPN, MPs’ procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples. Results: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2V617F mutation, history of thrombosis, platelets >400×109/l, hematocrit >45%, or leukocytes >10×109/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. Conclusion: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.
PrintDisplayed: 31/5/2024 22:25